Cliniphai provides secure, compliant AI agents and frameworks designed to optimize complex clinical trial workflows for life sciences organizations. Their Athena platform acts as an AI-powered marketplace connecting teams with certified localization providers for faster, accurate content management. This infrastructure enables sponsors and CROs to scale global submissions and patient communications while maintaining regulatory adherence.
Funding
Funding not disclosed
Founders
Product
Problem
The life sciences industry faces significant challenges in translating and localizing clinical trial materials, leading to delays, increased costs, and potential compliance issues. Traditional translation methods often lack the speed and accuracy required for global clinical trials, hindering effective communication and regulatory adherence.
Solution
Cliniphai offers Athena, an AI agent platform designed to streamline clinical trial localization and translation for the life sciences industry. Athena leverages advanced language models to provide fast, accurate, and compliant translations, accelerating clinical trials and improving global communication. The platform combines AI efficiency with human expertise through rigorous quality checks, ensuring translations meet the highest industry standards. By automating and enhancing the translation process, Cliniphai enables life science companies to maintain quality, reduce turnaround times, and adhere to regulatory requirements in global markets.
Target Audience
Cliniphai targets pharmaceutical, biotechnology, and medical device companies involved in global clinical trials and regulatory processes.
Features
- AI-powered translation engine utilizing state-of-the-art language models
- Support for a wide range of languages, including rare languages
- Regulatory compliance with ISPOR guidelines and industry-standard ISO certifications
- User-friendly platform for easy submission, tracking, and retrieval of translation projects
- Quality assurance processes combining AI and human expertise